Lords Mark Q2 FY27: consol PAT margin nearly halves to 4.6% as revenue rises 22% QoQ
margins compressing · miss vs street
₹375.73 Cr
₹17.26 Cr
4.55%
+20.3pp YoY
₹0.4
Lord's Mark Industries (formerly Kratos Energy & Infrastructure) reported consolidated revenue from operations of ₹375.73 Cr for Q2 FY27, up 22.1% QoQ from ₹307.68 Cr in Q1 FY27, but consolidated PAT fell 48.0% QoQ to ₹17.26 Cr from ₹33.18 Cr, taking net profit margin down to 4.59% from 10.61% and operating (EBITDA) margin to roughly 8.1% from about 16.0%. Standalone PAT of ₹15.83 Cr (EPS ₹0.37; consolidated EPS ₹0.40) tracked the same compression, confirming the squeeze sits at the parent level rather than in a subsidiary. A YoY comparison against the September-2025 quarter (revenue ₹12.64 Cr, loss ₹2.11 Cr) is not meaningful since that quarter predates the reverse amalgamation of Kratos Energy with Lords Mark India that created the current, much larger entity.
Q2 FY-2027 vs prior quarters
The margin bridge: cost of materials (purchase of stock-in-trade, the dominant line in this trading-heavy model) rose to about 83.5% of total income this quarter from roughly 75.3% in Q1, the main driver of the EBITDA compression. Finance costs rose 23.9% QoQ to ₹7.73 Cr as long-term borrowings jumped 53.8% half-on-half to ₹224.24 Cr (from ₹145.84 Cr at FY26-end), consistent with the board's October 19 proposal to raise up to ₹100 Cr via a promoter loan and with the ongoing Silvassa plant expansion and AI-dialysis-machine capex the company describes in its MD&A.
What the summary numbers don't show
No exceptional/extraordinary items this quarter in either statement (unlike FY26 full year's ₹4.18 Cr item)
FY27 revenue ₹1550 Cr (20% growth YoY). FY28 revenue >₹2000 Cr with PAT margin 10-11%. Medtech products expected Q4 FY27/Q1 FY28 launch. Dialysis 50 centers by FY27-end.
There is no formal sell-side consensus on this name (0-1 analysts per our pre-result tracking, rated Hold, though retail sentiment ran 85% Buy); our pre-result preview had flagged ~₹300-350 Cr revenue, 20-21% EBITDA margin and 12-13% PAT margin as the on-plan bar. The print beat the revenue range (₹375.7 Cr) but missed both margin targets by a wide margin. Management's own MD&A (Annexure 2) describes a 'massive jump in sales and profitability' in the medical-device division, 26 additional manufacturing licenses, and dialysis-machine trials underway in Bangalore — none of which is reflected in the consolidated P&L this quarter, where overall profitability fell sequentially; either the device division is still too small to move the group number or its gains were offset elsewhere. Management's FY27 guidance of ₹1,550 Cr revenue (given at the Q1 concall) is 44% met at the halfway mark (₹683.4 Cr H1 revenue), requiring roughly ₹866.6 Cr across H2 to hit the target — achievable at the current QoQ growth pace, but the FY28 goal of 10-11% PAT margin looks further away given this quarter's 4.6% print and the rising cost ratio. No formal guidance update was issued in this filing.
W1
Cost-of-materials ratio (83.5% of total income this quarter, up from 75.3% in Q1) needs to revert for PAT margin to rebuild toward the FY28 10-11% guidance from today's 4.6%
W2
H2 FY27 revenue run-rate needed (~₹866.6 Cr across two quarters) to hit the ₹1,550 Cr FY27 target after H1's ₹683.4 Cr (44% of target)
W3
Commercial launch of sickle-cell screening (flagged for January 2027) and AI-dialysis-machine export shipments (flagged from end-December) — management's own near-term catalysts in this filing's MD&A
Filing figures are in ₹ Lakh (converted ÷100 to Cr); no exceptional/extraordinary items this quarter in either statement (unlike FY26 full-year's ₹4.18 Cr item); year-ago quarter (Sep-2025) predates the Kratos Energy–Lords Mark India amalgamation (NCLT order), so YoY is not like-for-like — QoQ vs Q1 FY27 is the meaningful comparison.
Informational and educational content only. Not investment advice.